| abstract |
Provided is a modified coxsackievirus that has improved safety and/or aggressiveness and is usable in oncolytic virus therapy. Provided is a modified coxsackievirus which carries a mutant genome, wherein at least one polynucleotide comprising the target sequence of a tissue-specific microRNA (miRNA) has been inserted into the genome of coxsackievirus B3 wild type (CVB3-WT), and the growth of which is tissue-specifically inhibited. Further, it is preferred that the mutant genome has been inserted in such a manner as to allow the expression of a GM-CSF encoding region. |